BGJ398
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $227,808 | 13 | 0 |
| 2019 | $118,978 | 20 | 0 |
| 2018 | $973,991 | 73 | 0 |
| 2017 | $1.6M | 115 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 221 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II MULTICENTER SINGLE ARM STUDY OF ORAL BGJ398 INADULT PATIENTS WITH ADVANCED OR METASTATICCHOLANGIOCARCINOMA WITH FGFR2 GENE FUSIONS OR OTHER FGFR GENETIC ALTERATIONS WHO FAILED OR ARE INTOLERANT TOPLATINUM BASED CHEMOTHERAPY | Novartis Pharmaceuticals Corporation | $855,442 | 0 |
| MODULAR PHASE II STUDY TO LINK TARGETED THERAPY TO PATIENTS WITH PATHWAY ACTIVATED TUMORS MODULE 6 BGJ398 FOR PATIENTS WITH FGFR ALTERED TUMORS | Novartis Pharmaceuticals Corporation | $853,402 | 0 |
| A PHASE I OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF ORAL BGJ398 A PAN FGF R KINASE INHIBITOR IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $662,479 | 0 |
| A PHASE 2 MULTICENTER OPEN LABEL STUDY OF BGJ398 IN PATIENTS WITH RECURRENT RESECTABLE OR UNRESECTABLE GLIOBLASTOMA | Novartis Pharmaceuticals Corporation | $226,093 | 0 |
| A PHASE IB AND OR II STUDY OF BGJ398 IN COMBINATION WITH IMATINIB MESYLATE IN PATIENTS WITH UNTREATED ADVANCED GASTROINTESTINAL STROMAL TUMOR GIST | Novartis Pharmaceuticals Corporation | $177,043 | 0 |
| PILOT STUDY OF BGJ398 IN NON MUSCLE INVASIVE UROTHELIAL CARCINOMA | Novartis Pharmaceuticals Corporation | $46,099 | 0 |
| A PHASE IB OPEN LABEL STUDY OF ORAL BGJ398 IN COMBINATION WITH ORAL BYL719 IN ADULT PATIENTS WITH SELECT ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $38,135 | 0 |
| EFFICACY OF SINGLE AGENT BGJ398 IN FGFR1 3 TRANSLOCATED MUTATED OR AMPLIFIED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | Novartis Pharmaceuticals Corporation | $31,106 | 0 |
| A BIOLOGY STUDY OF THE MECHANISMS OF RESISTANCE TO TARGETED THERAPIES PLEASE NOTE THAT THIS IS A NON TREATMENT PROTOCOL | Novartis Pharmaceuticals Corporation | $10,100 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,920 | 6 |
Top Doctors Receiving Payments for BGJ398
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Webster, TX | $2.9M | 215 |
| , MD | Medical Oncology | New York, NY | $673.21 | 1 |
| , MD | Medical Oncology | Columbus, OH | $673.21 | 1 |
| , MD | Hematology & Oncology | Scottsdale, AZ | $673.21 | 1 |
| , MD | Hematology & Oncology | Boston, MA | $673.21 | 1 |
| , MD | Hematology & Oncology | Houston, TX | $673.21 | 1 |
| , MD | Internal Medicine | Boston, MA | $554.41 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.9M
- Total Doctors 6
- Transactions 221
About BGJ398
BGJ398 is a drug associated with $2.9M in payments to 6 healthcare providers, recorded across 221 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $227,808 was paid across 13 transactions to 0 doctors.
The most common payment nature for BGJ398 is "Unspecified" ($2.9M, 100.0% of total).
BGJ398 is associated with 10 research studies, including "A PHASE II MULTICENTER SINGLE ARM STUDY OF ORAL BGJ398 INADULT PATIENTS WITH ADVANCED OR METASTATICCHOLANGIOCARCINOMA WITH FGFR2 GENE FUSIONS OR OTHER FGFR GENETIC ALTERATIONS WHO FAILED OR ARE INTOLERANT TOPLATINUM BASED CHEMOTHERAPY" ($855,442).